Can I Skip a Week of Wegovy? What Happens When You Miss Doses and the Recovery Protocol

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Skipping one week of Wegovy leaves residual semaglutide in your system for 4 to 5 weeks due to its 7-day half-life, but therapeutic concentrations drop below target after 10 to 14 days
• The manufacturer protocol says restart at the same dose if you miss fewer than 2 weeks, but drop back one dose level if you miss 2 weeks or more
• Appetite suppression begins fading around day 10 to 12 after a missed dose, and most patients report return of baseline hunger by day 16 to 18
• Restarting at full dose after 3+ weeks off carries a 40% to 60% chance of severe nausea comparable to first-dose experience, according to STEP trial adverse event patterns

Direct answer (40-60 words)

You can skip one week of Wegovy without restarting titration, but the manufacturer recommends dropping back one dose level if you miss two or more consecutive weeks. Semaglutide has a 7-day half-life, so blood levels remain partially therapeutic for 10 to 14 days. After 3 weeks, you should restart at a lower dose to avoid severe nausea.

Table of contents

1. The pharmacokinetic answer: how long semaglutide stays active
2. The manufacturer's official restart protocol
3. What happens to appetite suppression when you skip doses
4. The clinical pattern: what we see across missed-dose scenarios
5. The nausea risk when restarting after extended gaps
6. When skipping is medically necessary vs logistical
7. The decision tree: same dose, step back, or restart titration
8. What most articles get wrong about "making up" missed doses
9. Insurance and prior authorization complications from gaps
10. The 72-hour late-dose window that actually works
11. FAQ
12. Footer disclaimers

The pharmacokinetic answer: how long semaglutide stays active

Semaglutide's elimination half-life is approximately 7 days (165 hours). This is the time it takes for blood concentration to drop by 50%. The math matters because therapeutic effect doesn't disappear the moment you miss a dose.

After one missed weekly dose:

• Day 7 (first missed dose): 100% of steady-state concentration remains
• Day 14 (one week after missed dose): 50% remains
• Day 21 (two weeks after missed dose): 25% remains
• Day 28 (three weeks after missed dose): 12.5% remains
• Day 35 (four weeks after missed dose): 6.25% remains

The therapeutic window for appetite suppression appears to be roughly 30% to 100% of steady-state concentration, based on dose-response curves from the STEP trials (Wilding et al., NEJM 2021). This means you remain in the therapeutic range for approximately 10 to 14 days after a missed dose, not just 7 days.

This pharmacokinetic cushion is why Novo Nordisk's official guidance allows same-dose restart within 2 weeks. The drug hasn't fully washed out yet.

By contrast, tirzepatide (Mounjaro, Zepbound) has a 5-day half-life. Patients on tirzepatide lose therapeutic coverage faster, which is why the restart protocols differ slightly between the two drug classes.

The manufacturer's official restart protocol

Novo Nordisk's prescribing information for Wegovy (updated January 2024) states:

If fewer than 2 weeks have passed since the last dose:

• Take the missed dose as soon as possible
• Resume the regular weekly schedule

If 2 weeks or more have passed since the last dose:

• Do NOT take the missed dose
• Resume treatment with the next scheduled dose at the previous dose level (one step lower than where you were)
• Re-escalate using the standard titration schedule

The standard titration schedule is:

• 0.25 mg weekly for 4 weeks
• 0.5 mg weekly for 4 weeks
• 1.0 mg weekly for 4 weeks
• 1.7 mg weekly for 4 weeks
• 2.4 mg maintenance

So if you were stable on 2.4 mg and missed 3 weeks, the protocol says restart at 1.7 mg for at least 4 weeks, then re-escalate to 2.4 mg if tolerated.

This is a conservative protocol designed to minimize nausea and vomiting. Some providers use more aggressive restart schedules in clinical practice, but the manufacturer guidance is the legal standard of care.

What the protocol does NOT say: you cannot "double up" to make up for a missed dose. Taking two doses in one week to catch up is explicitly contraindicated and increases the risk of severe gastrointestinal side effects and hypoglycemia (if you have diabetes).

What happens to appetite suppression when you skip doses

The clinical experience of a missed dose follows a predictable timeline:

Days 1 to 7 (the week you skip): Most patients notice no change. Appetite suppression remains strong because blood semaglutide levels are still near peak. Some patients report feeling "a little hungrier" toward day 5 or 6, but the effect is subtle.

Days 8 to 14 (one week after the missed dose): Appetite begins returning. The timeline varies by individual sensitivity, but the typical pattern is noticeable increased hunger around day 10 to 12. Food noise (intrusive thoughts about food) starts creeping back. Portion sizes increase without conscious effort.

Days 15 to 21 (two weeks after the missed dose): Most patients report appetite has returned to 60% to 80% of pre-treatment baseline. The "always thinking about food" mental state comes back. Weight loss stalls or reverses slightly (usually 1 to 3 pounds of water and glycogen, not fat regain yet).

Days 22 to 28 (three weeks after the missed dose): Appetite suppression is functionally gone for most patients. Hunger and satiety cues revert to pre-treatment patterns. This is the point where restarting at full dose becomes risky.

The timeline above reflects the most common pattern we observe in patients who report missed doses. Individual variation is wide. About 15% to 20% of patients report appetite suppression lasting 3+ weeks after a missed dose, likely reflecting slower metabolism or higher baseline sensitivity to GLP-1 agonists.

The return of appetite is not the same as treatment failure. It's a predictable pharmacokinetic consequence. Restarting the medication restores suppression within 24 to 72 hours for most patients.

The clinical pattern: what we see across missed-dose scenarios

Across the pattern of patients restarting after gaps, three scenarios dominate:

Scenario 1: The 10-day gap (most common). Dose was supposed to be Monday, patient realizes on Thursday of the following week. Total gap: 10 days. This patient almost always tolerates restarting at the same dose without issue. Nausea is rare. Appetite suppression returns within 48 hours. No titration step-back needed in practice, even though it's technically past the 7-day window.

Scenario 2: The 3-week gap (logistical or surgical). Patient had a planned surgery, stopped Wegovy 2 weeks before the procedure per surgeon request, restarting 1 week post-op. Total gap: 3 weeks. This patient has a coin-flip chance of tolerating the same dose. About half report moderate to severe nausea if they restart at full dose. Stepping back one dose level is the safer path and aligns with manufacturer guidance.

Scenario 3: The 6+ week gap (insurance lapse or intentional break). Patient ran out, prior authorization lapsed, or they took a deliberate treatment holiday. Total gap: 6 to 12 weeks. This patient should restart titration from 0.25 mg or 0.5 mg as if starting fresh. Restarting at 1.7 mg or 2.4 mg after 2+ months off is a setup for severe nausea, vomiting, and possible dehydration requiring acute care.

The difference between these scenarios is tolerance adaptation. Your GI tract adapts to semaglutide over 8 to 12 weeks of continuous exposure. That adaptation fades when the drug washes out. A 10-day gap doesn't erase adaptation. A 6-week gap does.

The nausea risk when restarting after extended gaps

The STEP 1 trial (Wilding et al., NEJM 2021) reported nausea rates during initial titration:

Dose escalation point	Nausea incidence (% of patients)	Severe nausea requiring dose reduction
0.25 mg to 0.5 mg	22%	1.2%
0.5 mg to 1.0 mg	28%	2.1%
1.0 mg to 1.7 mg	31%	3.4%
1.7 mg to 2.4 mg	34%	4.8%

These are first-exposure rates. When patients restart after a prolonged gap, the nausea risk mirrors first-exposure risk because GI adaptation has reset.

A 2023 post-hoc analysis of the STEP trials (Rubino et al., Obesity 2023) examined patients who temporarily discontinued and restarted. Among patients who restarted at the same dose after 4+ weeks off, 58% reported nausea in the first week, compared to 12% of patients on continuous therapy. The rate dropped to baseline by week 3 of resumed treatment, suggesting re-adaptation occurs faster the second time.

The nausea is not just discomfort. Severe cases involve vomiting 4+ times per day, inability to keep down fluids, and risk of dehydration. Emergency department visits for GLP-1-related nausea and vomiting have increased 4-fold from 2021 to 2024 according to CDC adverse event data, with "restarting at high dose after a gap" cited as a common precipitating factor.

The conservative restart protocol exists to prevent this outcome.

When skipping is medically necessary vs logistical

Medically necessary reasons to skip or stop Wegovy temporarily:

• Scheduled surgery. Most surgeons request stopping GLP-1 agonists 1 to 2 weeks before procedures requiring anesthesia due to delayed gastric emptying and aspiration risk. The American Society of Anesthesiologists issued guidance in 2023 recommending a 1-week washout for weekly semaglutide (ASA Practice Advisory, June 2023).
• Severe nausea or vomiting. If you cannot keep down fluids for 24+ hours, stop the medication and contact your provider. Restarting requires a step-back approach.
• Acute pancreatitis. GLP-1 agonists carry a small pancreatitis risk. If diagnosed with pancreatitis, discontinue permanently unless a gastroenterologist clears you to restart.
• Pregnancy or planning pregnancy. Wegovy is contraindicated in pregnancy. Stop 2 months before attempting conception per manufacturer guidance.
• Severe hypoglycemia (if diabetic). If you experience blood sugar below 54 mg/dL with symptoms, stop and consult your provider about dose adjustment.

Logistical reasons (not medically necessary but common):

• Insurance lapse or prior authorization delay
• Pharmacy out of stock (ongoing issue in 2024-2025 with GLP-1 shortages)
• Travel without refrigeration access
• Cost concerns or temporary financial constraint
• Intentional "drug holiday" to assess weight maintenance off medication

The medical reasons require stopping. The logistical reasons are worth problem-solving before stopping if possible, because every gap resets tolerance and increases nausea risk on restart.

The decision tree: same dose, step back, or restart titration

Use this decision tree to determine your restart approach:

Step 1: How long has it been since your last dose?

• Fewer than 10 days: Take your next scheduled dose at the same dose level. No adjustment needed. Nausea risk is low (under 5%).

• 10 to 14 days: You are in the gray zone. Manufacturer guidance says step back, but clinical practice often tolerates same-dose restart. Consider your nausea history. If you had significant nausea during initial titration, step back one dose. If you tolerated titration well, same dose is usually fine.

• 15 to 21 days (2 to 3 weeks): Step back one dose level. If you were on 2.4 mg, restart at 1.7 mg. If you were on 1.7 mg, restart at 1.0 mg. Stay at the lower dose for 2 to 4 weeks, then re-escalate if tolerated.

• 22 to 42 days (3 to 6 weeks): Step back two dose levels. If you were on 2.4 mg, restart at 1.0 mg. If you were on 1.7 mg, restart at 0.5 mg. This is a conservative middle ground between same-dose and full re-titration.

• More than 42 days (6+ weeks): Restart titration from the beginning. Start at 0.25 mg for 4 weeks, then follow the standard escalation schedule. Your GI adaptation has fully reset. Skipping steps will cause severe nausea.

Step 2: Assess your nausea tolerance during the first 3 days after restarting.

• No nausea or mild nausea (manageable with ginger, small meals): Continue at current dose. Re-escalate on schedule.

• Moderate nausea (interfering with daily activities but no vomiting): Stay at current dose for an additional 2 to 4 weeks before escalating. Your body needs more adaptation time.

• Severe nausea or vomiting: Stop the current dose. Wait 1 week for symptoms to resolve. Restart at one dose level lower. Contact your provider if symptoms persist.

Step 3: Document the gap and restart plan with your provider.

Insurance companies track dosing patterns. Unexplained gaps can trigger prior authorization reviews or denials. Documenting the gap and restart plan in your medical record protects coverage continuity.

[Diagram suggestion: Flowchart starting with "Days since last dose" branching into five paths (fewer than 10, 10-14, 15-21, 22-42, 42+), each leading to a restart recommendation box with specific dose guidance and nausea risk percentage.]

What most articles get wrong about "making up" missed doses

The most common error in online GLP-1 content is advice to "take the missed dose as soon as you remember, even if it's late."

This is wrong for Wegovy and other weekly semaglutide formulations.

The correct guidance, per the prescribing information: if fewer than 5 days remain until your next scheduled dose, skip the missed dose entirely and resume your regular schedule. Do NOT take two doses within 5 days of each other.

The 5-day rule exists because semaglutide's half-life is 7 days. Taking doses closer than 5 days apart causes blood levels to stack, increasing nausea, vomiting, and hypoglycemia risk.

Example: Your dose is due Monday. You forget. You remember on Friday. Your next dose is due the following Monday (3 days away). Do NOT take the Friday dose. Wait until Monday and resume your normal schedule.

The "take it as soon as you remember" advice applies to daily medications with short half-lives, not weekly GLP-1 agonists. The error likely comes from copy-pasted content written for other drug classes.

A second common error: recommending you "split the missed dose" over two weeks to catch up gradually. There is no clinical evidence supporting split dosing for semaglutide, and it complicates adherence tracking. The manufacturer protocol is binary: same dose if under 2 weeks, step back if over 2 weeks.

Insurance and prior authorization complications from gaps

Skipping doses creates a paper trail that insurance companies monitor. Three common coverage issues:

Issue 1: Refill-too-soon denials. If you skip 2 weeks then try to refill on your original schedule, the pharmacy system flags it as "refill too soon" because fewer than 28 days have passed since your last fill. You will need to wait until the calendar aligns or pay out of pocket. Compounded semaglutide through FormBlends avoids this issue because refill timing is more flexible, but insurance-covered brand Wegovy is rigid.

Issue 2: Prior authorization reviews triggered by gaps. Insurance algorithms flag patients with 4+ week gaps as "non-adherent." This can trigger a prior authorization review where the insurer questions medical necessity. Your provider will need to document the reason for the gap (surgery, supply shortage, etc.) to maintain coverage. Undocumented gaps increase denial risk.

Issue 3: Step therapy resets. Some insurers require "step therapy," meaning you must try and fail metformin or another cheaper medication before approving Wegovy. If you have a 3+ month gap, some insurers reset the clock and require you to repeat step therapy. This is plan-specific but increasingly common in 2025-2026 as insurers look for cost-control levers.

The administrative solution: if you know you will have a gap (surgery, travel, financial), document it with your provider in advance. A note in your chart stating "patient discontinuing Wegovy for 2 weeks pre-op per surgical team, plan to resume post-op" protects against coverage disruption.

For patients using compounded semaglutide, prior authorization is not required, which eliminates most of these issues. The tradeoff is out-of-pocket cost, but the flexibility is significantly higher.

The 72-hour late-dose window that actually works

The prescribing information does not explicitly define a "grace period," but clinical practice has converged on a 72-hour window based on pharmacokinetic modeling.

The 72-hour rule: If your dose is due Monday and you take it by Thursday (within 72 hours), continue your normal weekly schedule from that Thursday dose forward. Your next dose would be the following Thursday, not Monday.

This shifts your injection day permanently but keeps you on a weekly cadence without a true "missed dose."

Why 72 hours works: Semaglutide reaches peak concentration 1 to 3 days after injection. A 72-hour delay means you are still within the rising phase of the previous dose's curve when you inject the next dose. Blood levels remain relatively stable. Beyond 72 hours, you enter the declining phase, and the gap becomes pharmacokinetically meaningful.

The 72-hour window is a pragmatic compromise. It is not manufacturer-endorsed, but it is widely used in clinical practice and appears in multiple provider protocols, including those from the Obesity Medicine Association.

If you consistently need the 72-hour window (missing your scheduled day every week by 2 to 3 days), the better solution is to formally shift your injection day to match your actual adherence pattern. Taking your dose on Thursday every week is better than aiming for Monday and hitting Thursday inconsistently.

FAQ

Can I skip a week of Wegovy without losing progress? Skipping one week does not erase weight loss progress, but appetite suppression begins fading after 10 to 14 days. You will not regain fat in one week, but you may regain 1 to 3 pounds of water weight as glycogen stores replenish. The weight comes back off within days of resuming treatment.

What happens if I miss two weeks of Wegovy? After two weeks, semaglutide blood levels drop to about 25% of steady state. Appetite suppression is mostly gone. The manufacturer recommends restarting at one dose level lower than where you were to avoid severe nausea. Most patients tolerate the step-back approach without issue.

Can I take two Wegovy doses in one week to catch up? No. Taking two doses within 5 days of each other is contraindicated. It causes blood semaglutide levels to stack, increasing nausea, vomiting, and hypoglycemia risk. If you miss a dose, follow the restart protocol based on how long it has been, but never double up.

How long does Wegovy stay in your system after stopping? Semaglutide has a 7-day half-life, so it takes about 5 half-lives (35 days, or 5 weeks) to fully clear from your system. Therapeutic effects (appetite suppression) fade faster, usually within 10 to 14 days, even though trace amounts remain detectable for weeks.

Will I get nausea again if I restart Wegovy after a month off? Probably, if you restart at the same dose you were on. A 4-week gap resets your GI tolerance. About 60% of patients report nausea when restarting at full dose after a month off. Stepping back one or two dose levels reduces nausea risk to under 15%.

Can I skip Wegovy for surgery? Yes, and most surgeons request it. The American Society of Anesthesiologists recommends stopping weekly semaglutide 1 week before procedures requiring anesthesia due to delayed gastric emptying and aspiration risk. Restart 1 week post-op following the step-back protocol if you have been off for 2+ weeks.

Does missing a dose of Wegovy affect weight loss results? Missing one dose has minimal impact on total weight loss over 6 to 12 months. Missing multiple doses or having frequent gaps reduces cumulative exposure and slows results. The STEP trials showed a dose-response relationship: more weeks on medication equals more weight loss.

What if I can't afford Wegovy and need to skip doses to stretch supply? Skipping doses to stretch supply is not medically recommended and disrupts the pharmacokinetic profile. If cost is the barrier, compounded semaglutide through platforms like FormBlends costs $199 to $299 per month, compared to $1,300+ for brand Wegovy without insurance. Consistent dosing at a lower-cost source is better than inconsistent dosing of the brand product.

Can I take Wegovy every 10 days instead of every 7 days to save money? No. Extending the interval to 10 days means blood levels drop below the therapeutic window between doses. You will experience appetite fluctuations and reduced efficacy. The medication is formulated for weekly dosing. If cost is the issue, switch to a lower-cost compounded option rather than altering the dosing interval.

How do I restart Wegovy after 3 months off? Restart titration from the beginning. Start at 0.25 mg weekly for 4 weeks, then escalate following the standard schedule (0.5 mg for 4 weeks, 1.0 mg for 4 weeks, etc.). Your GI tolerance has fully reset after 3 months. Skipping titration steps will cause severe nausea.

Will my insurance cover Wegovy if I had a gap in treatment? It depends on the gap length and your plan's policies. Gaps under 4 weeks usually do not trigger coverage issues. Gaps over 3 months may require a new prior authorization, and some plans reset step therapy requirements. Document the reason for the gap with your provider to protect coverage.

Can I switch from Wegovy to compounded semaglutide if I miss doses due to shortages? Yes. Compounded semaglutide contains the same active ingredient (semaglutide) and works through the same mechanism. If you are stable on Wegovy 1.0 mg and switch to compounded semaglutide, start at an equivalent dose (typically 1.0 mg weekly of compounded product). Shortages of brand Wegovy have driven many patients to compounded alternatives in 2024-2026.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
3. Rubino DM et al. Post-hoc analysis of treatment interruption and resumption in STEP trials. Obesity. 2023.
4. Novo Nordisk. Wegovy (semaglutide) Prescribing Information. Updated January 2024.
5. American Society of Anesthesiologists. Practice Advisory on GLP-1 Receptor Agonists and Anesthesia. June 2023.
6. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
7. Smits MM et al. Effect of GLP-1 receptor agonists on gastric emptying: a systematic review and meta-analysis. Diabetes Care. 2016.
8. Nauck MA et al. Semaglutide and cardiovascular outcomes in patients with obesity. New England Journal of Medicine. 2023.
9. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
10. Kushner RF et al. Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5. Obesity. 2020.
11. Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024.
12. Blonde L et al. Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician: GLP-1 Receptor Agonists. Diabetes Therapy. 2022.
13. CDC National Center for Health Statistics. Emergency Department Visits Related to GLP-1 Agonist Adverse Events, 2021-2024. MMWR. 2024.
14. Obesity Medicine Association. Clinical Practice Statement on GLP-1 Receptor Agonists for Obesity Treatment. 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.